Published in Biotech Business Week, May 3rd, 2004
The international pivotal trial is designed to compare the overall survival differential resulting from the combination of YM's drug, tesmilifene, with the anthracycline, epirubicin, and cyclophosphamide against the use of epirubicin/cyclophosphamide alone in women with metastatic breast cancer.
"We are very pleased to have commenced this important trial on time, and anticipate to have completed enrolment in approximately 18 months," said Mr. David Allan, chairman and chief executive officer of YM...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.